Effect of Pharmacological Agents on Survival in Patients With Degenerative Mitral Stenosis: Results From a Cohort of 1004 Patients

Tyagi, Gaurav; Dang, Patricia; Pasca, Ioana; Patel, Reena; Pai, Ramdas G.

doi:10.1016/s0735-1097(12)62033-6

Cited by 3 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For example, in Western countries the combination of MS and AS affects mostly the aging population and has a degenerative etiology [ 19 ]. The latter doesn’t imply commissural fusion, which usually results in less severe stenosis than in rheumatic disease [ 20 , 21 ]. Other rarer aetiologies include iatrogenic (both drug-induced and post-radiotherapy) and genetic (such as mucopolysaccharidosis) conditions.…”

Section: Echocardiographic Assessmentmentioning

confidence: 99%

Non-Invasive Assessment of Multivalvular Heart Disease: A Comprehensive Review

De Zan,

van der Bilt,

Broekhuizen

et al. 2024

Rev. Cardiovasc. Med.

View full text Add to dashboard Cite

Multivalvular heart disease (MVD) implies the presence of concomitant valvular lesions on two or more heart valves. This condition has become common in the few last years, mostly due to population aging. Every combination of valvular lesions uniquely redefines the hemodynamics of a patient. Over time, this may lead to alterations in left ventricle (LV) dimensions, shape and, eventually, function. Since most of the echocardiographic parameters routinely used in the valvular assessment have been developed in the context of single valve disease and are frequently flow- and load-dependent, their indiscriminate use in the context of MVD can potentially lead to errors in judging lesion severity. Moreover, the combination of non-severe lesions may still cause severe hemodynamic consequences, and thereby systolic dysfunction. This review aims to discuss the most frequent combinations of MVD and their echocardiographic caveats, while addressing the opportunities for a multimodality assessment to achieve a better understanding and treatment of these patients.

show abstract

Section: Echocardiographic Assessmentmentioning

confidence: 99%

Non-Invasive Assessment of Multivalvular Heart Disease: A Comprehensive Review

De Zan,

van der Bilt,

Broekhuizen

et al. 2024

Rev. Cardiovasc. Med.

View full text Add to dashboard Cite

show abstract

“…Degenerative progression was highly variable but generally slow. Nevertheless, diabetes mellitus seemed to accelerate the progression while the use of beta blockers was associated with a protective effect 23 …”

Section: Clinical Presentation and Natural Historymentioning

confidence: 99%

Mitral valve stenosis in the current era: a changing landscape

Giannini

Mazzola

Pugliese

et al. 2022

Journal of Cardiovascular Medicine

View full text Add to dashboard Cite

Mitral stenosis results from haemodynamic obstruction at the mitral valve level because of structural abnormalities of the valve apparatus, leading to increased resistance to the transmitral flow. Although rheumatic fever remains the predominant cause of mitral stenosis worldwide, other causes are increasingly relevant in the developed countries with degenerative mitral stenosis (DMS) because of mitral annulus calcification (MAC) becoming growingly prevalent in industrialized countries with higher life expectancy. Rheumatic mitral stenosis (RMS) and DMS display dramatic differences in pathophysiology, prognosis, and disease progression. Furthermore, to date, robust evidence regarding the management of DMS because of MAC is lacking. Nevertheless, new diagnostic techniques and catheter-based interventions are changing this landscape and paving the way to a significant reduction in DMS-related morbidity and mortality. Here we briefly review the current knowledge on the pathophysiology, diagnosis and treatment of DMS and RMS, underscoring the current diagnostic and therapeutic pathways, as well as persisting uncertainties and perspectives.

show abstract

“…Calcification of the leaflets and/or mitral annulus occurring in patients without RHD is a degenerative process seen in association with comorbidities, 12 including chronic kidney disease with its attendant elevated parathyroid hormone levels, diabetes, and coronary artery disease. 13 Uncommonly, MS may be related to congenital, eosinophilic, or carcinoid heart disease and rarely, secondary to radiation; these causes of mitral obstruction typically do not include commissural fusion 14 hence PBMV is unlikely to be beneficial. However, calcification of the mitral leaflets, subvalvular apparatus, and, in particular, the annulus in these nonrheumatic subsets results in obstruction of flow and can be confused with rheumatic MS, although the characteristic anatomic features in Figure 1 will be missing.…”

Section: Introductionmentioning

confidence: 99%

The 40th Anniversary of Percutaneous Balloon Valvuloplasty for Mitral Stenosis: Current Status

Turi¹

2022

Structural Heart

View full text Add to dashboard Cite

Effect of Pharmacological Agents on Survival in Patients With Degenerative Mitral Stenosis: Results From a Cohort of 1004 Patients

Cited by 3 publications

References 0 publications

Non-Invasive Assessment of Multivalvular Heart Disease: A Comprehensive Review

Non-Invasive Assessment of Multivalvular Heart Disease: A Comprehensive Review

Mitral valve stenosis in the current era: a changing landscape

The 40th Anniversary of Percutaneous Balloon Valvuloplasty for Mitral Stenosis: Current Status

Contact Info

Product

Resources

About